Compugen (CGEN) FCF Margin (2009 - 2010)
Compugen (CGEN) posted quarterly FCF Margin of 483.68% for Q4 2010, up 812032.0% year-over-year from N/an in Q4 2009, and up 94.38% on a QoQ basis from 8604.0% in Q4 2009.
Powered by 
Analysis
Compugen (CGEN) FCF Margin (2009 - 2010) Analysis & Trends
Compugen has reported FCF Margin for 2 years, with the latest figure at 483.68% in Q4 2010.
- FCF Margin for Q4 2010 came in at 483.68%, up 812032.0% year-over-year; the trailing twelve-month figure through Dec 2010 was 113.95% (down 584173.0% YoY), and the FY2025 annual result was 43.05%, down 13454.0% from the prior year.
- FCF Margin grew to 483.68% in Q4 2010, from 8604.0% in the prior quarter.
- Over five years, FCF Margin peaked at 981.25% in Q3 2009 and troughed at 8604.0% in Q4 2009.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Compugen | 242.44 Mn | 156.82 Mn | -92,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2010 | -435.26% |
| Dec 31, 2009 | -8,220.00% |
| Sep 30, 2009 | 981.25% |